GRAND RAPIDS, Mich., Dec. 14 /PRNewswire-FirstCall/ -- BestNet
Communications Corp. (OTC Bulletin Board: BESC) announced today that it is
in the process of making a number of basic changes as a result of entering
the medical device field, which will include changing its name from BestNet
Communications Corporation to "Oncologix Tech Inc."
    In addition to the name change, the other changes in process are
increasing the authorized capital and increasing the number of shares
allocated to our Stock Plan for the compensation of key employees. These
changes, which were adopted by the written consent of a majority of the
shareholders, are expected to become effective upon the completion of a
number of procedural steps required by law, including filing of an
Information Statement with the SEC, mailing it to all of the shareholders
and filing necessary papers with the State of Nevada, where BestNet is
incorporated.
    According to Mr. Stanley L. Schloz, chief executive officer; "We
believe the new name, Oncologix Tech, Inc., better reflects the new
direction of BestNet and its wholly owned subsidiary Oncologix Corp. This
new branding, along with the increased authorized capital and the greater
number of shares for the stock plan, will enable Oncologix Tech Inc. to
promote and support itself as a biotechnology company."
    Mr. Schloz went on to explain that doubling the number of authorized
common stock shares from 100,000,000 to 200,000,000 would facilitate the
raising of additional capital. He also stated that the increased allocation
of shares to the Company's Stock Plan would "provide a means of attracting
and retaining the kind of skilled people we will need as we move ahead in
the medical field."
    Additionally, Mr. Schloz commented that Dr. Andrew S. Kennedy, Chief
Science and Medical Officer of Oncologix Corp., has been invited to present
on "Factors Related To Toxicity and Response in 680 Treatments of Resin
90Y- Microspheres Radioembolization in Hepatic Malignancies" at the 18th
International Congress on Anti Cancer Treatment (ICACT) in Paris, France on
February 8, 2007.
    The ICACT is an annual international educational and scientific
meeting. Its aim is to provide comprehensive updates and the state of the
art treatments in the management of cancer. Leading scientists from around
the world participate at this scientific meeting giving educational
lectures on the state of the art in cancer treatments.
    Dr. Kennedy was quoted as saying, "It is a privilege to share this
collaborative data on behalf of my co-investigators. The presentation at
this important meeting will represent the largest collection of data
presented to date on the treatment of liver cancer with microsphere
brachytherapy. The ICACT provides an opportunity to exchange ideas and
discuss the results and developments in cancer treatments like microspheres
with leading researchers in the field."
    About BestNet Communications Corp. and Oncologix Corp.:
    BestNet Communications is a global solutions provider of long distance;
conference calling, ClicktoPhone and custom application-based communication
services. BestNet's services are accessed worldwide via the Internet,
standard phones and wireless devices and are delivered using standard phone
lines and equipment. This results in a cost effective high quality service
for both businesses and consumers.
    Under the brand name Bestnetcall(TM) (http://WWW.BESTNETCALL.COM) the
services offer subscribers premium quality calls and conference calling, at
significantly lower rates. Calls and conference calls can also be launched
via a desktop application or handheld devices including Palm(TM), Pocket
PC(R) and Blackberry(TM) and used with any standard or wireless phone. In
addition the company's new ClicktoPhone(TM) service
(http://WWW.CLICKTOPHONE.COM) enables clients to add secure and anonymous
voice communication connectivity anywhere in the world to web sites, web
banners, pictures, electronic documents, and customized e-mail calling
buttons.
    Contact BestNet at: investors@bestnetcom.com
    Oncologix Corporation, based in Atlanta GA, is a wholly owned
subsidiary of BestNet Communications. Oncologix develops advanced medical
treatments for soft tissue cancers.
    This release contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, which are
intended to be covered by the "safe harbor" created thereby. These
statements include the plans and objectives of management for future
operations, including plans and objectives. The forward-looking statements
herein are based on current expectations that involve judgments with
respect to, among other things, future economic, competitive and market
conditions and future business decisions, all of which are difficult or
impossible to predict accurately and many of which are beyond control of
the company. Although the company believes that the assumptions underlying
the forward-looking statements are reasonable, any one of the assumptions
could be inaccurate and, therefore, can be no assurance that the
forward-looking statements included in this release will prove to be
accurate.

Link to this page: